PT1303521E - Derivados de tetra-hidro-heterocicloazepinil-pirimidina - Google Patents

Derivados de tetra-hidro-heterocicloazepinil-pirimidina

Info

Publication number: PT1303521E
Authority: PT; Portugal
Prior art keywords: heterocycloazepinyl; hydro; tetra; pyrimidine derivatives; pyrimidine
Prior art date: 2000-07-18

Application number

PT01978247T

Other languages

English (en)

Inventor

Wolfgang Wostl

Hans-Peter Maerki

Alfred Binggeli

Maurice Wilhelm

Mutel Vincent

Original Assignee

Hoffmann La Roche

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-07-18

Filing date

2001-07-16

Publication date

2005-05-31

2001-07-16 Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche

2005-05-31 Publication of PT1303521E publication Critical patent/PT1303521E/pt

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Cardiology (AREA)
Psychiatry (AREA)
Addiction (AREA)
Heart & Thoracic Surgery (AREA)
Pain & Pain Management (AREA)
Hospice & Palliative Care (AREA)
Urology & Nephrology (AREA)
Virology (AREA)
Diabetes (AREA)
Psychology (AREA)
Endocrinology (AREA)
Tropical Medicine & Parasitology (AREA)
Ophthalmology & Optometry (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Hematology (AREA)
Molecular Biology (AREA)
Vascular Medicine (AREA)
Emergency Medicine (AREA)
AIDS & HIV (AREA)
Obesity (AREA)
Reproductive Health (AREA)

PT01978247T 2000-07-18 2001-07-16 Derivados de tetra-hidro-heterocicloazepinil-pirimidina PT1303521E (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP00115450		2000-07-18
PCT/EP2001/008186 WO2002006288A1 (en)	2000-07-18	2001-07-16	Tetrahydro-heterocycloazepinyl pyrimidine derivatives

Publications (1)

Publication Number	Publication Date
PT1303521E true PT1303521E (pt)	2005-05-31

Family

ID=8169290

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PT01978247T PT1303521E (pt)	2000-07-18	2001-07-16	Derivados de tetra-hidro-heterocicloazepinil-pirimidina

Country Status (17)

Country	Link
US (1)	US6369222B1 (pt)
EP (1)	EP1303521B1 (pt)
JP (1)	JP4060705B2 (pt)
KR (1)	KR100525214B1 (pt)
CN (1)	CN1187358C (pt)
AR (1)	AR031715A1 (pt)
AT (1)	ATE288437T1 (pt)
AU (2)	AU2002210418B2 (pt)
BR (1)	BR0112586A (pt)
CA (1)	CA2415966C (pt)
DE (1)	DE60108759T2 (pt)
DK (1)	DK1303521T3 (pt)
ES (1)	ES2236317T3 (pt)
MX (1)	MXPA03000428A (pt)
PT (1)	PT1303521E (pt)
WO (1)	WO2002006288A1 (pt)
ZA (1)	ZA200300163B (pt)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1074549B1 (en) *	1999-08-06	2003-11-19	F. Hoffmann-La Roche Ag	Tetrahydro-benzo(d)azepines and their use as antagonists at metabotropic glutamate receptors
DE10238722A1 (de)	2002-08-23	2004-03-11	Bayer Ag	Selektive Phosphodiesterase 9A-Inhibitoren als Arzneimittel zur Verbesserung kognitiver Prozesse
DE10238724A1 (de)	2002-08-23	2004-03-04	Bayer Ag	Alkyl-substituierte Pyrazolpyrimidine
US20040215284A1 (en) *	2003-01-30	2004-10-28	Recordati S.A.	Treatment of neuromuscular dysfunction of the lower urinary tract with selective mGlu5 antagonists
DE10320785A1 (de)	2003-05-09	2004-11-25	Bayer Healthcare Ag	6-Arylmethyl-substituierte Pyrazolopyrimidine
DE10328479A1 (de)	2003-06-25	2005-01-13	Bayer Ag	6-Arylamino-5-cyano-4-pyrimidinone
DE102004001873A1 (de)	2004-01-14	2005-09-29	Bayer Healthcare Ag	Cyanopyrimidinone
DE102004019708A1 (de) *	2004-04-20	2005-11-17	Basf Ag	Offenzellige Schaumstoffe und Verfahren zu ihrer Herstellung
CN1980710B (zh) *	2004-06-30	2013-06-12	阿特西斯公司	作为5-羟色胺受体调节剂的取代的氮杂环庚烯衍生物
EP2439207A1 (en)	2004-10-04	2012-04-11	Millennium Pharmaceuticals, Inc.	Lactam Compounds Useful as Protein Kinase Inhibitors
EP1963337B1 (en) *	2005-12-20	2010-09-01	Richter Gedeon Nyrt.	THIENO[2,3-b]PYRIDINE DERIVATIVES
PE20080145A1 (es)	2006-03-21	2008-02-11	Janssen Pharmaceutica Nv	Tetrahidro-pirimidoazepinas como moduladores de trpv1
ES2380165T3 (es) *	2007-08-02	2012-05-09	Recordati Ireland Limited	Nuevos compuestos heterocíclicos como antagonistas mGlu5
WO2009068617A1 (en)	2007-11-30	2009-06-04	Boehringer Ingelheim International Gmbh	1, 5-dihydro-pyrazolo (3, 4-d) pyrimidin-4-one derivatives and their use as pde9a modulators for the teatment of cns disorders
JP5562865B2 (ja)	2007-12-17	2014-07-30	ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ	Ｔｒｐｖ１のイミダゾロ−、オキサゾロ−、及びチアゾロピリミジン・モジュレーター
UA105362C2 (en)	2008-04-02	2014-05-12	Бьорингер Ингельхайм Интернациональ Гмбх	1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
PE20110383A1 (es)	2008-09-08	2011-07-15	Boehringer Ingelheim Int	Pirazolopirimidinonas como inhibidores de la fosfodiesterasa 9a (pde9a)
JP5684719B2 (ja)	2008-12-05	2015-03-18	ミレニアムファーマシューティカルズ，インコーポレイテッドＭｉｌｌｅｎｎｉｕｍＰｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ．	Ｐｌｋ阻害剤としての５，７−ジヒドロ−６ｈ−ピリミド［５、−４ｄ］［１］ベンゾアゼピン−６−チオン
WO2010089119A1 (en)	2009-02-04	2010-08-12	Recordati Ireland Limited	Heterocyclic derivatives as m-glu5 antagonists
GEP20146098B (en)	2009-03-31	2014-05-27	Boehringer Ingelheim Int	1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their usage as pde9a modulators
WO2011029633A1 (en)	2009-09-14	2011-03-17	Recordati Ireland Limited	Heterocyclic mglu5 antagonists
CN103097391B (zh)	2010-07-09	2015-04-08	雷科尔达蒂爱尔兰有限公司	作为mGlu5拮抗剂的新型螺环杂环化合物
CN105541849B (zh)	2010-08-12	2018-03-23	勃林格殷格翰国际有限公司	6‑环烷基‑1,5‑二氢‑吡唑并[3,4‑d]嘧啶‑4‑酮衍生物及其作为PDE9A抑制剂的用途
US8809345B2 (en)	2011-02-15	2014-08-19	Boehringer Ingelheim International Gmbh	6-cycloalkyl-pyrazolopyrimidinones for the treatment of CNS disorders
US8822464B2 (en)	2011-11-28	2014-09-02	Boehringer Ingelheim International Gmbh	N-aryl-piperazine derivatives and their use as positive allosteric modulators of mGluR5 receptors
US8741892B2 (en)	2011-12-05	2014-06-03	Boehringer Ingelheim International Gmbh	Compounds
US8846948B2 (en)	2011-12-13	2014-09-30	Boehringer Ingelheim International Gmbh	Compounds
US8796467B2 (en) *	2011-12-13	2014-08-05	Boehringer Ingelheim International Gmbh	Compounds
US8937176B2 (en)	2011-12-14	2015-01-20	Boehringer Ingelheim International Gmbh	Compounds
US8716277B2 (en)	2011-12-14	2014-05-06	Boehringer Ingelheim International Gmbh	Substituted imidazole compounds useful as positive allosteric modulators of mGlu5 receptor activity
US8883789B2 (en)	2011-12-14	2014-11-11	Boehringer Ingelheim International Gmbh	Piperazine derivatives and their use as positive allosteric modulators of mGluR5 receptors
US8889677B2 (en)	2012-01-17	2014-11-18	Boehringer Ingellheim International GmbH	Substituted triazoles useful as mGlu5 receptor modulators

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3940395A (en) *	1969-08-29	1976-02-24	American Home Products Corporation	4-Amino-2-phenyl-6-thiopryimidines
BG17968A3 (bg) *	1970-08-14	1974-03-05	Dr. Karl Thomae Gmbh	Метод за получаване на производни на азепина
BE790287A (fr) *	1971-10-28	1973-04-19	Delalande Sa	Acides pyrimidin-6yl acethydroxamiques, leur procede de preparation et leur application en therapeutique
FR2608607B1 (fr)	1986-12-23	1989-04-28	Sanofi Sa	Procede de preparation de thienylethylamines et dithienylethylamines ainsi obtenues
DE3820775A1 (de)	1988-06-20	1989-12-21	Thomae Gmbh Dr K	Neue 4,5,7,8-tetrahydro-6h-thiazolo(5,4,-d)azepine, ihre herstellung und ihre verwendung als arzneimittel
ATE124694T1 (de) *	1990-11-06	1995-07-15	Pfizer	Chinazolinderivate um die antitumorwirkung zu verbessern.

2001
- 2001-07-11 US US09/902,916 patent/US6369222B1/en not_active Expired - Fee Related
- 2001-07-16 AU AU2002210418A patent/AU2002210418B2/en not_active Ceased
- 2001-07-16 ES ES01978247T patent/ES2236317T3/es not_active Expired - Lifetime
- 2001-07-16 BR BR0112586-9A patent/BR0112586A/pt not_active Application Discontinuation
- 2001-07-16 EP EP01978247A patent/EP1303521B1/en not_active Expired - Lifetime
- 2001-07-16 WO PCT/EP2001/008186 patent/WO2002006288A1/en active Search and Examination
- 2001-07-16 MX MXPA03000428A patent/MXPA03000428A/es active IP Right Grant
- 2001-07-16 CA CA002415966A patent/CA2415966C/en not_active Expired - Fee Related
- 2001-07-16 JP JP2002512190A patent/JP4060705B2/ja not_active Expired - Fee Related
- 2001-07-16 PT PT01978247T patent/PT1303521E/pt unknown
- 2001-07-16 AT AT01978247T patent/ATE288437T1/de not_active IP Right Cessation
- 2001-07-16 DE DE60108759T patent/DE60108759T2/de not_active Expired - Lifetime
- 2001-07-16 AU AU1041802A patent/AU1041802A/xx active Pending
- 2001-07-16 CN CNB018128459A patent/CN1187358C/zh not_active Expired - Fee Related
- 2001-07-16 DK DK01978247T patent/DK1303521T3/da active
- 2001-07-16 KR KR10-2003-7000783A patent/KR100525214B1/ko not_active IP Right Cessation
- 2001-07-16 AR ARP010103373A patent/AR031715A1/es not_active Application Discontinuation
2003
- 2003-01-07 ZA ZA200300163A patent/ZA200300163B/en unknown

Also Published As

Publication number	Publication date
CA2415966A1 (en)	2002-01-24
EP1303521B1 (en)	2005-02-02
JP4060705B2 (ja)	2008-03-12
AU2002210418B2 (en)	2006-08-17
ATE288437T1 (de)	2005-02-15
JP2004504324A (ja)	2004-02-12
AR031715A1 (es)	2003-10-01
DK1303521T3 (da)	2005-06-13
ES2236317T3 (es)	2005-07-16
KR20030015397A (ko)	2003-02-20
US6369222B1 (en)	2002-04-09
EP1303521A1 (en)	2003-04-23
DE60108759D1 (de)	2005-03-10
WO2002006288A1 (en)	2002-01-24
CN1441804A (zh)	2003-09-10
AU1041802A (en)	2002-01-30
CN1187358C (zh)	2005-02-02
DE60108759T2 (de)	2006-05-11
MXPA03000428A (es)	2003-06-24
ZA200300163B (en)	2004-04-07
KR100525214B1 (ko)	2005-11-01
CA2415966C (en)	2009-10-27
US20020045635A1 (en)	2002-04-18
BR0112586A (pt)	2003-05-20

Publication	Publication Date	Title
DK1292604T3 (da)	2009-06-15	2-Aminocarbonyl-9H-purinderivater
PT1303521E (pt)	2005-05-31	Derivados de tetra-hidro-heterocicloazepinil-pirimidina
PT1406628E (pt)	2006-06-30	Derivados de tera-hidroquinolina
ATE298332T1 (de)	2005-07-15	Decahydro-isochinolinderivate
DK1280809T3 (da)	2005-11-07	Antitumorecteinascidinderivater
DE50114491D1 (de)	2008-12-24	Substituierte C-Cyclohexylmethylamin-Derivative
FR2810318B1 (fr)	2005-09-23	Derives de diamano-phenothiazine
AR028602A1 (es)	2003-05-14	Derivados de pirrol
PT1268453E (pt)	2006-10-31	Metabolitos de agonista/antagonista de estrogenio
PT1154988E (pt)	2004-12-31	Derivados de mevinolina
AR028282A1 (es)	2003-04-30	Derivados de aminofenil pirimidona
PT1187815E (pt)	2006-06-30	Derivados de 4-fenil-pirimidina
PT1351959E (pt)	2005-09-30	Novos derivados de pleuromutilina
DK1322593T3 (da)	2004-10-11	O-substituerede-6-methyl-tramadol-derivater
ATE282021T1 (de)	2004-11-15	Substituierte aminomethyl-phenyl- cyclohexanderivate
PT1317179E (pt)	2004-08-31	Formulacoes de mesotriona
AR027931A1 (es)	2003-04-16	Antitranspirantes
PT1246791E (pt)	2005-03-31	Derivados de aminometilfenilciclo-hexanona
PT1088818E (pt)	2005-03-31	Derivados de quinolin-4-ilo
PT1194401E (pt)	2004-02-27	Derivados de diacil-hidrazina
DE50112454D1 (de)	2007-06-14	Substituierte 5-amino-1-penten-3-ol-derivate
ATE374776T1 (de)	2007-10-15	Pyrrolotriazolopyrimidinonderivate
NO20024393D0 (no)	2002-09-13	2-fenylpyran-4-on-derivater
DK1246793T3 (da)	2005-02-21	Substituerede aminomethyl-phenyl-cyclohexanderivater